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Globally, antimicrobial resistance is one of the most important public health challenges in 44 
which the clinical microbiology laboratory plays a critical role by providing guidance for 45 
antimicrobial treatment. Despite the recognition of its importance, there is still a real need for 46 
standardized training of clinical microbiologists and harmonisation of diagnostic procedures. 47 
This is particularly true for veterinary clinical microbiology where additional challenges exist 48 
when microbiologists are trying to fulfil a professional role very similar to their colleagues 49 
working in human microbiology laboratories. The specific points that need addressing to 50 
improve the outputs of veterinary microbiology laboratories discussed here include 1) 51 
harmonisation of methodologies used by veterinary laboratories for antimicrobial 52 
susceptibility testing (AST); 2) specific guidelines for interpretation and reporting of AST 53 
results for animal pathogens; 3) guidelines for detection of antimicrobial resistance 54 
mechanisms in animal isolates; 4) standardisation of diagnostic procedures for animal clinical 55 
specimens and 5) the need to train more veterinary clinical microbiology specialists. 56 
However, there is now a plan to address these issues led by the European Network for 57 
Optimisation of Veterinary Antimicrobial Treatment (ENOVAT) which is bringing together 58 
experts in veterinary microbiology, pharmacology, epidemiology and antimicrobial 59 
stewardship from Europe and wider afield. ENOVAT is aiming to work with project partners 60 
towards standardisation and harmonisation of laboratory methodologies and optimisation of 61 
veterinary antimicrobial treatment. Ultimately, the project may provide a mechanism for 62 
standardisation and harmonisation of veterinary clinical microbiology methodologies, which 63 













Antimicrobial resistance (AMR) is a global multifactorial issue, which endangers the ability 68 
to treat bacterial infections and hinders the implementation of important medical advances 69 
(i.e. complex surgeries, chemotherapy) in both human and veterinary medicine. The 70 
emergence of AMR has highlighted the key role that clinical microbiology laboratories play 71 
in driving antimicrobial stewardship and appropriate antimicrobial use (1).  72 
Underuse or suboptimal use of microbiological culture and antimicrobial susceptibility 73 
testing (AST) and overreliance on empirical antimicrobial therapy can exacerbate AMR in 74 
both human and veterinary settings; therefore, in order to overcome these obstacles a closer 75 
partnership between diagnostic laboratories and clinicians is required for successful 76 
antimicrobial stewardship (1, 2). In addition, there have been calls for standardized training 77 
of clinical microbiologists, and a better understanding of the professional identity of clinical 78 
microbiologists in line with the recognition received by other specialities (3, 4). If calls for a 79 
greater professional recognition are warranted in human clinical microbiology where the field 80 
is already seen as an integral element of antimicrobial stewardship, a similar need exists for 81 
both closer laboratory-clinic collaboration and improved recognition of the role of clinical 82 
microbiologists in veterinary settings. To facilitate these needs, standardized training of 83 
veterinary clinical microbiologists, a better recognition of the clinical microbiologist’s role in 84 
patient care and harmonization of professional standards is needed in veterinary clinical 85 
microbiology. In addition, several major challenges exist for veterinary microbiology 86 
laboratories, which we discuss here.  87 
Harmonizing methodologies of antimicrobial susceptibility testing (AST) in veterinary 88 
laboratories. 89 
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Although international antimicrobial susceptibility testing (AST) standards for microbiology 90 
laboratories exist and are largely applicable to veterinary settings 91 
(https://www.iso.org/standard/70464.html), their implementation is dependent on local 92 
factors. Furthermore, currently there is no worldwide consensus for usage of a common 93 
methodology in veterinary laboratories. When performing culture and AST, veterinary 94 
laboratories generally follow methodologies developed for processing human clinical 95 
isolates. In that regard, laboratories adhere to either the European Committee on 96 
Antimicrobial Susceptibility Testing (EUCAST) or the American Clinical and Laboratory 97 
Standards Institute (CLSI) guidelines or, less commonly, guidelines issued by various 98 
national committees. This approach serves the immediate needs of clinicians and the data can 99 
be useful for detecting shifts in local antimicrobial susceptibility patterns. However, the use 100 
of multiple standards is a major limitation when comparing susceptibility data between 101 
laboratories or countries, thereby compromising global AMR surveillance in animal 102 
pathogens. Hence, early detection of emergent resistant pathogens or meaningful comparison 103 
of resistance rates within or between countries is hampered, as shown in a study comparing 104 
antimicrobial susceptibility data in canine urinary tract infections isolates from across Europe 105 
(5). Similarly, human studies have shown that the usefulness of AMR surveillance is often 106 
jeopardised by variability in laboratory procedures or non-compliance with international 107 
reporting standards (6). In addition,  the quality management guidance provided by CLSI for 108 
monitoring antimicrobial resistance trends using  cumulative susceptibility data provided by 109 
human epidemiologic studies (7) also needs to be followed in veterinary surveillance 110 
programmes. 111 
Lack of specific guidelines for interpretation and reporting of AST results for animal 112 
pathogens 113 
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Although Veterinary Antimicrobial Susceptibility Testing subcommittees have been 114 
established within both the CLSI (-VAST) and EUCAST (VetCAST), there is still a shortage 115 
of animal-, infection- and pathogen-specific clinical breakpoints (CBPs) for antimicrobial 116 
drugs used in veterinary medicine. Both subcommittees are actively developing more clinical 117 
breakpoints for veterinary antimicrobial agents; however, this is a slow process due to the 118 
complexity of the tasks for various pathogen-antimicrobial combinations in different 119 
infections and animal hosts. In the meantime, the lack of specific interpretative criteria for 120 
animal pathogens represents a great difficulty for laboratory staff. Thus, developing best 121 
practice guidelines for interpreting and reporting AST results for animal pathogens for which 122 
CBPs are not yet available must be regarded as a priority for the veterinary profession.  123 
Lack of guidelines for detection of AMR mechanisms in clinical companion animal 124 
isolates 125 
AMR is widespread in companion and livestock animals (8, 9), and accurate detection and 126 
identification of resistant organisms is paramount for infection control and preventing 127 
zoonotic transmission. Although harmonisation of methods and interpretative criteria for 128 
monitoring AMR in zoonotic and commensal bacteria from healthy food-producing animals 129 
has been established through the EU-Commission Decision 2013/652/EU 130 
(https://www.eumonitor.eu/9353000/1/j9vvik7m1c3gyxp/vk0vn25n5e9o ), AMR surveillance 131 
in companion animals, primarily cats, dogs and horses, has not been included. Veterinary 132 
laboratories, which  actively perform AMR surveillance, often follow either the CLSI (10) or 133 
EUCAST procedures  134 
(https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Resistance_mechanisms/135 
EUCAST_detection_of_resistance_mechanisms_170711.pdf) for specific detection of 136 
resistance mechanisms; however, these are not entirely applicable for veterinary clinical 137 
isolates. For instance, consensus on detection methods for methicillin-resistance in important 138 
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animal pathogens such as methicillin-resistant Staphylococcus pseudintermedius (MRSP) or 139 
S. schleiferi (MRSS), is still lacking (10, 11). In addition, detection of these and other 140 
multidrug resistant (MDR) organisms emerging in companion animals [e.g. carbapenem-141 
resistant Escherichia coli and Acinetobacter baumannii (12, 13)] are often restricted to 142 
specialised research laboratories, raising the question of whether many AMR issues remain 143 
undetected. All of this points to a clear need for guidance for veterinary laboratories on 144 
screening and reporting policies, including when to refer emerging multidrug resistant 145 
(MDR) organisms to specialist laboratories.  146 
Standardisation of diagnostic procedures for animal clinical specimens 147 
The absence of specific guidelines and methodologies for processing animal clinical 148 
specimens for microbiology testing is a well-recognised and serious challenge to the 149 
profession (14). Consequently, there is an urgent need for standardisation of the diagnostic 150 
process from sample collection, processing, pathogen identification, selection of isolates for 151 
AST and reporting, in veterinary laboratories across all veterinary services providers. Such a 152 
lack of specific guidelines for common procedures in veterinary laboratories has multiple 153 
implications that influence the appropriate diagnosis and clinical management of infections, 154 
directly impacting on antimicrobial stewardship. Thus, AMR surveillance programs may 155 
become ineffectual, therapeutic interventions inappropriate and significant zoonoses may go 156 
undetected. A comprehensive set of recommended clinical microbiology procedures, 157 
covering all stages of microbiological investigations, is necessary to ensure common 158 
standards across microbiology laboratories processing veterinary specimens. These should 159 
include guidelines for (i) clinical specimen collection and laboratory management specific to 160 
the clinical condition/animal species, (ii) specimen-specific culture, (iii) organism isolation 161 
and identification, (iv) selection of relevant bacterial pathogens for AST, and (v) the 162 
interpretation and reporting of culture and susceptibility results. A widely available resource 163 
 on F








for such protocols, similar to what is available for human microbiology laboratories in the 164 
UK [Standards for Microbiology Investigations (UK SMIs); 165 
https://www.gov.uk/guidance/uk-standards-for-microbiology-investigations-smi-quality-and-166 
consistency-in-clinical-laboratories] should be created through a similar consultation process 167 
involving all partners and organisations active in this field. Ideally, these laboratory 168 
procedures should be standardised at a European level and made available to all veterinary 169 
microbiology laboratories. In addition, a new framework for Microbiology Investigation 170 
Criteria for Reporting Objectively (MICRO) to ensure accurate and comparable microbiology 171 
laboratory results are produced among human laboratories, has been recently published and 172 
could be adopted by veterinary laboratories (15).  173 
Although the points highlighted here are long-held goals, there is now a plan for action which 174 
is being led by the European Network for Optimisation of Veterinary Antimicrobial 175 
Treatment (ENOVAT). ENOVAT is an EU COST Action project bringing together experts in 176 
veterinary microbiology, pharmacology, epidemiology and antimicrobial stewardship 177 
throughout Europe and wider afield via collaborations with Near Neighbour Countries and 178 
International Partner Countries. Amongst other important objectives 179 
(https://enovat.eu/about/), ENOVAT is aiming to use online surveys to critically review the 180 
current methodologies and interpretive criteria used by veterinary microbiology diagnostic 181 
laboratories and identify gaps and challenges of microbiological diagnostic procedures. The 182 
survey outcome will provide an invaluable data source which can be used to draw a roadmap 183 
outlining how ENOVAT can work with project partners towards standardisation and 184 
harmonisation of veterinary microbiology methodologies.  185 
The role of veterinary clinical microbiologists in the context of emerging molecular 186 
technologies  187 
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Similar to humans, animal infections are often caused by opportunistic pathogens residing in 188 
the commensal bacterial population, making interpretation of culture results and pathogen 189 
selection for AST challenging (16). Optimisation of this process requires the expertise of a 190 
clinical microbiologist, ideally with a veterinary background to guide the laboratory technical 191 
staff, to give advice at all analytical stages, and to facilitate the dialogue between the 192 
laboratory and clinicians. Such dialogue is increasingly important due to the advent and 193 
uptake of new laboratory diagnostic technologies. For example, matrix-assisted laser 194 
desorption ionization–time of flight mass (MALDI-TOF) spectrometry is increasingly 195 
adopted as the gold standard for bacterial and fungal identification in the veterinary 196 
microbiology laboratories (17-19). MALDI-TOF has revolutionised clinical microbiology by 197 
introducing an easy to perform, rapid, low-cost method of identification; however, veterinary 198 
microbiologists need also to be aware of the new challenges arising as the low-cost of testing 199 
per isolate can lead to more isolates being identified to species level compared to the pre-200 
MALDI-TOF era. To reduce the risks of “over identification”, a very careful process of 201 
“clinical microbiology reasoning” needs to be undertaken by the bench microbiologist to 202 
ensure that only isolates which are clinically relevant are selected for AST (20, 21).  203 
Although the occurrence of technical errors in laboratory testing is reduced by following 204 
quality control programs, interpretation of culture results should integrate multiple clinical 205 
and laboratory factors to identify and pursue clinically significant bacterial isolates. The 206 
wealth of knowledge built up in human clinical microbiology studies shows that 207 
underestimation of the value of this process can lead to testing and reporting of organisms not 208 
associated with infection and hence  contributing to inappropriate or ineffective antimicrobial 209 
therapy (22).  210 
Furthermore, new molecular tools aiming to improve diagnostic quality or speed up result 211 
turnaround time, have emerged in clinical microbiology. These molecular diagnostic 212 
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technologies are designed to detect single or multiple pathogen(s) (bacterial, viral or fungal) 213 
associated with clinical syndromes. These molecular tools include point of care tests 214 
(POCTs), gene-based resistance detection platforms, single or multiplex PCR assays, 215 
immune-chromatographic tests, peptide nucleic acid fluorescent in situ hybridization (FISH) 216 
technologies, loop-mediated isothermal assays (LAMP), mass spectrometry and next-217 
generation sequencing (21, 23).  POCTs, also known as “rapid diagnostic tests” or “near 218 
patient tests”, are used in both human and animal settings; these, are designed to be used 219 
outside the laboratory and to generate results under an hour allowing timely interventions. A 220 
recent study which has sought to identify POCTs currently available for diagnosing animal 221 
disease in developing countries, has found that many POCTs target a small number of key 222 
zoonotic animal diseases, while few exist for other important animal diseases (24). This study 223 
also highlighted that the lack of validation regulations for veterinary POCTs has allowed tests 224 
which have been improperly validated to enter the market, presenting challenges for 225 
customers and undermining their true potential on disease control (24). Multiplex PCR assays 226 
have the advantage of simultaneously detecting multiple bacterial, viral and/or fungal 227 
pathogens likely to be associated with a particular clinical syndrome (e.g., respiratory, 228 
gastrointestinal (GI), sepsis or central nervous system (CNS) infections); however, the 229 
disadvantage is that novel unsuspected pathogens may be missed (21). These multiplex 230 
detection platforms have gained a place in human and veterinary clinical practice as they 231 
support timely detection and clinical management decisions but have also introduced 232 
challenges in the clinical microbiology laboratory. These include evaluation of cost-value 233 
analysis, integration of molecular platforms in the laboratory workflow and the need for 234 
experienced specialists for results interpretation and monitoring results accuracy (21). Not 235 
last, these molecular advances include next  generation sequencing (NGS) and 236 
bioinformatics, which are increasingly used for high resolution typing of pathogens or 237 
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plasmids during hospital outbreaks, detection of genes associated with antimicrobial 238 
resistance or pathogenicity, although they are more commonly undertaken as part of research 239 
investigation (25). The role of whole genome sequencing (WGS) in predicting AST was 240 
reviewed by Ellington M. J. et al., and concluded that currently, for most bacterial species 241 
there is insufficient evidence to support the use of WGS-inferred AST to guide clinical 242 
decision-making (26). Furthermore, direct pathogen detection in clinical specimens 243 
(metagenomics NGS) via Nanopore MinION sequencing is gaining popularity due to the 244 
advantages provided by its novel features (compact portable device providing real-time 245 
sequencing and analysis) allowing easier integration in the microbiology laboratory workflow 246 
(27).  However, the transition of NGS from research to the clinical human and veterinary 247 
clinical laboratory setting seems to be a distant prospect due to its complexity and the need 248 
for expert input, especially bioinformatics knowledge required for interpretation of results, as 249 
well as validation and quality assurance (28). The issue around availability and integration of 250 
molecular diagnostics in the human and veterinary routine microbiology laboratory workflow 251 
are even more profound in developing countries due to poor infrastructures, financial 252 
inequities and lack of training. In addition, there is a lack of effective AMR surveillance 253 
networks and diagnostic capacity in both human and animal populations in developing 254 
countries, leading to an increase use of broad-spectrum antimicrobials by health professionals 255 
(29).  256 
As the technical advances continue to emerge in clinical microbiology, careful integration of 257 
what is technically possible with what is clinically relevant, will require regular appropriate 258 
training of staff to keep pace with the developments in the field (23, 27). This highlights the 259 
importance of the veterinary clinical microbiology training and specialisation, which has a 260 
longstanding history in America where the American College of Veterinary Microbiology 261 
was formed in 1968 (https://www.acvm.us/about-acvm/). .  In Europe, the formation of the 262 
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European College of Veterinary Microbiology (ECVM) became reality in 2016 263 
(https://ebvs.eu/colleges/ECVM). In addition, the Study Group of Veterinary Microbiology 264 
(ESGVM), established within the European Society for Clinical Microbiology and Infectious 265 
Diseases, also promotes the need for training and specialisation in veterinary microbiology in 266 
Europe 267 
(https://www.escmid.org/research_projects/study_groups/study_groups_o_z/veterinary_micr268 
obiology/). Furthermore, the European Association for Veterinary Diagnosticians (EAVLD, 269 
https://www.eavld.org/eavld/) provides a platform for networking and communication among 270 
veterinary laboratories.  271 
Ultimately, the increasing threat from AMR and zoonotic emerging infectious diseases is 272 
underlying the need to improve and integrate veterinary microbiology services with public 273 
health services worldwide, to provide the backbone of a global One Health approach. 274 
Ensuring that veterinary microbiology laboratory have the technical facilities and the 275 
expertise of veterinary microbiology specialists, provides the necessary infrastructure to 276 
change and adapt to new challenges such as the one represented by the SARS-Cov-2 277 
pandemic. This major public health issue  has created unprecedented pressure on the global 278 
health services and provided an opportunity for veterinary microbiology services to rise to the 279 
challenge and show their adaptability by joining the global effort of controlling the pandemic 280 
through PCR testing when it most needed it (30).  281 
Summary 282 
Within the ENOVAT project, we are developing united complementary approaches within 283 
the veterinary microbiology profession to help achieve the long-held goals of harmonisation 284 
of AST methods and standardisation of diagnostic procedures across veterinary microbiology 285 
laboratories in Europe and beyond. We are also lobbying for more training of clinical 286 
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veterinary microbiologists to enable the roll out of high quality diagnostic and treatment 287 
protocols for animals. This would ensure the implementation of common strategies and a 288 
level playing field across all laboratories, which will positively reduce the AMR burden and 289 
ultimately improve animal and public health. The outcomes may well bring benefits to 290 
veterinary diagnosticians worldwide. 291 
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